title: The impact of donor age on the outcome of adult living donor liver transplantation.
abstract: BACKGROUND
  The negative effects of increased donor age on liver transplantation became evident in deceased donor liver transplantation. In living donor liver transplantation (LDLT), the details remain unclear.
  
  
  METHODS
  Initially, 137 adult LDLT recipients from August 1996 to May 2005 were divided into two groups (donors <50 years of age: n=99, donors >or= 50 years of age: n=38) for the retrospective study. Then, 24 recipients who received LDLT from June 2005 to July 2006 were divided into two groups: group 1 (donors <50 years of age, n=14) and group 2 (donors >or= 50 years of age, n=10) and enrolled in the prospective study to analyze their clinical course and prognostic factors in the aged graft.
  
  
  RESULTS
  In the retrospective study, the younger donor group had significantly better survival than that of the aged donor group (P=0.015, Log rank test). In the prospective study, the postoperative graft functions showed that the serum total bilirubin levels were significantly lower in group 1 (P<0.02, by ANOVA analysis). The phosphorylated-Signal Transducer and Activator of Transcription3 expression at 4 hr after reperfusion (RT2) in group 2 was significantly lower than that in group 1. At RT2, the expressions were up-regulated in group 1, but were down-regulated in group 2. The serum 8-hydroxydeoxyguanosine value became significantly higher in group 1 two weeks after LDLT.
  
  
  CONCLUSIONS
  In the near term, Signal Transducer and Activator of Transcription3 gene induction during cold preservation may be of great use in improving the outcome of aged grafts in LDLT.
authors.affiliation: Department of Gastroenterological Transplant Surgery and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry, Okayama City, Okayama, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Takahito
authors.initials: T
authors.lastname: Yagi
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Umeda
authors.forename: Daisuke
authors.initials: D
authors.lastname: Sato
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Matsukawa
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Susumu
authors.initials: S
authors.lastname: Shinoura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sadamori
authors.forename: Kenji
authors.initials: K
authors.lastname: Mizuno
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Yoshida
authors.forename: Noriaki
authors.initials: N
authors.lastname: Tanaka
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000097:blood; D006498:Hepatectomy / Q000401:mortality; D006801:Humans; D008099:Liver; D019520:Living Donors; D008875:Middle Aged; D018579:Patient Selection; D012189:Retrospective Studies; D050794:STAT1 Transcription Factor / Q000235:genetics; D050795:STAT2 Transcription Factor / Q000235:genetics; D050796:STAT3 Transcription Factor / Q000235:genetics; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D050794:STAT1 Transcription Factor; D050795:STAT2 Transcription Factor; D050796:STAT3 Transcription Factor; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine